L870810

a small-molecule inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties, has an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore; structure in first source

Also Known As:

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Debnath, Bikash: 1 article (11/2012)
2.	Ding, Jian: 1 article (11/2012)
3.	Kazemi, Roza: 1 article (11/2012)
4.	Long, Ya-Qiu: 1 article (11/2012)
5.	Neamati, Nouri: 1 article (11/2012)
6.	Odde, Srinivas: 1 article (11/2012)
7.	Sanchez, Tino W: 1 article (11/2012)
8.	Wang, Yong: 1 article (11/2012)
9.	Xie, Hua: 1 article (11/2012)
10.	Xu, Shili: 1 article (11/2012)

Related Diseases

1.	Neoplasms (Cancer) 11/26/2012 - "Because of its desirable pharmacological and pharmaceutical properties we were intrigued to design novel analogues of L-870,810 with goals to (1) improve upon limitations of naphthyridine-7-carboxamides as antiviral agents and (2) to reposition their use as innovative cytotoxic agents for cancer therapeutics. "
2.	Infections 01/01/2008 - "EVG and L-870,810 both inhibited the replication of murine leukemia virus and simian immunodeficiency virus, suggesting that IN inhibitors bind to a conformationally conserved region of various retroviral IN enzymes and are an ideal drug for a range of retroviral infections."

Related Drugs and Biologics

1.	Enzymes
2.	Cytotoxins (Cytolysins)
3.	Antiviral Agents (Antivirals)

Related Therapies and Procedures

1.	Therapeutics